CaseyLO'ConnellMDFACP

Clotting Disorder, Myeloproliferative Disorder Hematology-Oncology

Associate Professor of Clinical Medicine, Lawrence & Janice Kelly Chair in Hematology, Director, Gehr CURES Myeloid Malignancies Program

Join to view full profile

Dr. O'Connell is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. O'Connell's full profile

Already have an account?

Office
1441 Eastlake Ave
Ste 8302E
Los Angeles, CA 90089
Phone+1 323-865-3105

Fax+1 323-865-0060

Education & Training

University of Southern California/LAC+USC Medical CenterFellowship, Hematology, 2006 - 2007
University of Southern California/LAC+USC Medical CenterFellowship, Medical Oncology, 2005 - 2006
University of Southern California/LAC+USC Medical CenterFellowship, Hematology, 2004 - 2005
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 2001 - 2004
George Washington University School of Medicine and Health SciencesClass of 2001

Certifications & Licensure

CA State Medical License 2002 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

Super Doctor SuperDoctors.com

Clinical Trials

Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed Start of enrollment: 2016 Nov 02
Active, not recruiting
Phase 1, Phase 2
Recombinant EphB4-HSA Fusion Protein and Azacitidine or Decitabine for Relapsed or Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Patients Previously Treated With a Hypomethylating Agent Start of enrollment: 2017 Apr 20
Terminated
Phase 2
Epigenetics, Vitamin C, and Abnormal Blood Cell Formation - Vitamin C in Patients With Low-Risk Myeloid Malignancies Start of enrollment: 2017 Nov 21
Active, not recruiting
Not Applicable
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) Start of enrollment: 2021 Feb 09
Active, not recruiting
Phase 1, Phase 2
Actuate 1901: 9-ING-41 in Myelofibrosis Start of enrollment: 2020 Aug 20
Completed
Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

1 citations
Tranexamic Acid in the Treatment of Refractory Gastrointestinal Arteriovenous Malformation Bleeding in Left Ventricular Assist Device Patients.
Michael W. Fong, Noam Morningstar-Kywi, Casey O'Connell, Uzma Qureshi, Emily E. Han
Circulation. Heart Failure. 2021-11-22
3 citations
Ruxolitinib discontinuation in polycythemia vera: Patient characteristics, outcomes, and salvage strategies from a large multi-institutional database.
Douglas Tremblay, Lukas Ronner, Nikolai A. Podoltsev, Jason Gotlib, Mark L. Heaney
Leukemia Research. 2021-05-27
10 citations
Extrapulmonary Manifestations of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection
Hugo R. Rosen, Casey O'Connell, Mitra K. Nadim, Brittney DeClerck, Sarah Sheibani
Journal of Medical Virology. 2021-05-01

Abstracts/Posters

Landmark Response and Survival Analyses from 206 AML Patients Treated with Guadecitabine in a Phase 2 Study Demonstrate the Importance of Adequate Treatment Duration t...
Casey L. O'Connell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Persistent Leukocytosis in Polycythemia Vera Is Associated with Disease Evolution but Not Thrombosis: An Analysis from a 520-Patient Retrospective Multi-Center Database
Casey L. O'Connell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Results from a Phase 2 Study of Navitoclax in Combination with Ruxolitinib in Patients with Primary or Secondary Myelofibrosis
Casey L. O'Connell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ...
Casey L. O'Connell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
A Randomized, Open-Label, Multicenter, Phase 2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of KRT-232 Compared with Ruxolitinib in Patients with Phleb...
Casey L. O'Connell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Final Results of Prospective Treatment with Pegylated Interferon Alfa-2a for Patients with Polycythemia Vera and Essential Thrombocythemia in First and Second-Line Set...
Casey L. O'Connell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Landmark Response and Survival Analyses from 102 MDS and CMML Patients Treated with Guadecitabine in a Phase 2 Study Showing That Maximum Response and Survival Is Best...
Casey L. O'Connell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Durable Remission and Long-Term Survival in Relapsed/Refractory (r/r) AML Patients Treated with Guadecitabine, Median Survival Not Reached for Responders after Long Te...
Casey L. O'Connell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Phase I Results of a Multicenter Clinical Trial Combining Guadecitabine, a DNA Methyltransferase Inhibitor, with Atezolizumab, an Immune Checkpoint Inhibitor, in Patie...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediat...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018